Shares of Corium International Inc. (NASDAQ:CORI) gapped up before the market opened on Tuesday . The stock had previously closed at $4.13, but opened at $4.19. Corium International shares last traded at $4.65, with a volume of 17,588 shares traded.

Several research firms recently issued reports on CORI. WBB Securities upgraded Corium International from a “hold” rating to a “speculative buy” rating and set a $11.00 target price for the company in a research report on Tuesday, May 3rd. FBR & Co reissued a “buy” rating on shares of Corium International in a research note on Monday, May 2nd. Jefferies Group reissued a “buy” rating and set a $9.00 price target on shares of Corium International in a research note on Wednesday, May 11th. Leerink Swann reissued a “buy” rating and set a $14.00 price target on shares of Corium International in a research note on Wednesday, May 18th. Finally, Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research note on Tuesday, June 21st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $11.58.

The stock’s 50 day moving average is $3.90 and its 200-day moving average is $4.45. The company’s market capitalization is $99.63 million.

Corium International (NASDAQ:CORI) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.10. On average, equities research analysts predict that Corium International Inc. will post ($1.70) earnings per share for the current fiscal year.

In other news, Director Eric Bjerkholt acquired 24,500 shares of Corium International stock in a transaction that occurred on Thursday, May 19th. The stock was purchased at an average price of $3.64 per share, for a total transaction of $89,180.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Corium International stock. Turner Investments L.P. boosted its position in shares of Corium International Inc. (NASDAQ:CORI) by 97.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,520 shares of the biopharmaceutical company’s stock after buying an additional 97,520 shares during the period. Turner Investments L.P. owned 0.89% of Corium International worth $1,604,000 at the end of the most recent reporting period.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.